Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus (SLE) is a chronic, usually life-long, potentially fatal autoimmune disease characterized by unpredictable exacerbations and remissions with variable clinical manifestations. In SLE there is a high probability for clinical involvement of the joints, skin, kidney, brain, lung, heart, serosa and gastrointestinal tract.
Women and minorities are disproportionately affected and SLE is most common in women of child-bearing age although it has ben reported in both extremes of life (e.g. diagnosed in infants and in the tenth decade of life). The prevalence in the Unites States had been estimated as approximately 500,000 but a recent telephone survey commissioned by the Lupus Foundation of America suggested a prevalence of as many as 2,000,000. A recent study identified a prevalence of 500 per 100,000 (1:200) in women residing in the area surrounding the city of Birmingham, Great Britain.
Medical care by experienced clinicians with access to state of the art diagnostic and therapeutic measures will result in improved outcomes for patients with SLE. In addition, preventive measures such as influenza and pneumococcal vaccination, TB testing, and patient education regarding the dangers of ultraviolet light, a prudent diet, and exercise will also assure patient satisfaction and improved health status. Such services are available at the Center for Arthritis and Autoimmunity as well as the Seligman Center for Advanced Therapeutics.
For more information call:
Center for Arthritis and Autoimmunity: 212-598-6516;
or the Seligman Center for Advanced Therapeutics: 646-356-9400.